A Phase 1b Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With Alzheimer's Disease Receiving Standard-of-care
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2019
Price : $35 *
At a glance
- Drugs HTL 18318 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Heptares Therapeutics
- 26 Jul 2018 Last checked against the ClinicalTrials.gov record.
- 19 Jul 2018 Status changed from recruiting to completed.
- 09 Mar 2018 New trial record